Resilience selection: a grave potential bias in clinical trials
DOI:
https://doi.org/10.18203/2349-3259.ijct20261391Keywords:
Resilience, Randomised control trials, Adverse events, ITT, Correction for resilience, GLP-1RA drugsAbstract
Physiological and psychological resilience has important implications for health, disease and treatment. Resilience is shown to boost treatment compliance as well as response and thereby reduce mortality. We consider the possibility that individuals having lower resilience are more likely to discontinue treatment in response to side effects of a drug. In randomized control trials (RCT) if a considerable proportion of individuals discontinue from the treatment group because of side effects, the average resilience in the remaining treatment group would be greater. As a result, the frequency or severity of adverse outcomes in the treatment group will be smaller than the control even when the drug has no effect. This bias is more likely to be serious for drugs with more frequent and/or serious side effects, but following intention to treat (ITT) protocols with some additional precautions can help in avoiding it. We suggest testable predictions of the resilience selection bias hypothesis along with ways to quantify and correct for the bias in RCTs. Attempts to detect, measure and correct for the resilience selection bias should be considered necessary for realistic evaluation of drug action in a clinical trial. Retrospective studies are more sensitive to RS bias than RCTs and need to be interpreted carefully.
References
Richardson GE. The metatheory of resilience and resiliency. J Clin Psychol. 2002;58(3):307-21. DOI: https://doi.org/10.1002/jclp.10020
Faria DA, Revoredo LS, Vilar MJ, Eulália MCM. Resilience and treatment adhesion in patients with systemic lupus erythematosus. Open Rheumatol J. 2014;8:1-8. DOI: https://doi.org/10.2174/1874312920140127001
Meraz R, McGee J, Ke W, Osteen K. Resilience mediates the effects of self-care activation and hope on medication adherence in heart failure patients. Res Nursing Heal. 2023;46(3):323-35. DOI: https://doi.org/10.1002/nur.22312
Saedi F, Dehghan M, Mohammadrafie N, Xiao X, Alaa HH, Mohammad AZ. Predictive role of spiritual health, resilience, and mental well-being in treatment adherence among hemodialysis patients. BMC Nephrol. 2024;25(1):326. DOI: https://doi.org/10.1186/s12882-024-03768-8
Kim GM, Lim JY, Kim EJ, Park SM. Resilience of patients with chronic diseases: A systematic review. Health Social Care Comm. 2019;27(4):797-807. DOI: https://doi.org/10.1111/hsc.12620
Kennedy B, Fang F, Valdimarsdóttir U, Udumyan, R, Montgomery S, Fall K. Stress resilience and cancer risk: a nationwide cohort study. J Epidemiol Community Heal. 2017;71(10):947-53. DOI: https://doi.org/10.1136/jech-2016-208706
Udumyan R, Montgomery S, Fang F, Valdimarsdottir U, Fall K. Stress Resilience in Late Adolescence and Survival among Cancer Patients: A Swedish Register-Based Cohort Study. Cancer epidemiology, biomarkers and prevention. Am Associat Cancer Res. 2019;28(2):400-8. DOI: https://doi.org/10.1158/1055-9965.EPI-18-0451
Blanc J, Seixas A, Donley T, Bubu OM, Williams N, Jean-Louis G. Resilience factors, race/ethnicity and sleep disturbance among diverse older females with hypertension. J Affect Disord. 2020;271:255-61. DOI: https://doi.org/10.1016/j.jad.2020.03.148
Babić R, Babić M, Rastović P, Ćurlin M, Šimić J, Mandić K, et al. Resilience in Health and Illnes. Psychiatria Danubina. 2020;32(2):226-32.
Alim TN, Lawson WB, Feder A, Iacoviello BM, Saxena S, Bailey CR, et al. Resilience to meet the challenge of addiction: psychobiology and clinical considerations. Alcohol Res. 2012;34(4):506-15. DOI: https://doi.org/10.35946/arcr.v34.4.14
Rogers A, Leslie F. Addiction neurobiologists should study resilience. Addict Neurosci. 2024;11:100152. DOI: https://doi.org/10.1016/j.addicn.2024.100152
Nishimi K, Bürgin D, O'Donovan A. Psychological resilience to lifetime trauma and risk for cardiometabolic disease and mortality in older adults: A longitudinal cohort study. J Psychosomat Res. 2023;175:111539. DOI: https://doi.org/10.1016/j.jpsychores.2023.111539
Zhang A, Zhou L, Meng Y, Ji, Q, Ye M, Liu Q, et al. Association between psychological resilience and all-cause mortality in the Health and Retirement Study. BMJ Mental Heal. 2024;27(1):e301064. DOI: https://doi.org/10.1136/bmjment-2024-301064
Galvin JE, Kleiman MJ, Chrisphonte S, Cohen I, Disla S, Galvin CB, et al. The Resilience Index: A Quantifiable Measure of Brain Health and Risk of Cognitive Impairment and Dementia. J Alzheimer's Dis. 2021;84(4):1729-46. DOI: https://doi.org/10.3233/JAD-215077
Sehgal P, Ungaro RC, Foltz C, Iacoviello B, Dubinsky MC, Keefer L. High Levels of Psychological Resilience Associated with Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease. Inflammat Bowel Dis. 2021;27(6):791-6. DOI: https://doi.org/10.1093/ibd/izaa196
Nova T. A guide to measure resilience. 2023. Available at: https://resiliencei.com/blog/a-guide-to-measuring-resilience. Accessed on 20 January 2026.
Ghulam A, Bonaccio M, Costanzo S, Bracone F, Gianfagna F, de Gaetano G et al. Psychological Resilience, Cardiovascular Disease, and Metabolic Disturbances: A Systematic Review. Front Psychol. 2022;13:817298. DOI: https://doi.org/10.3389/fpsyg.2022.817298
Lean MEJ, Leslie WS, Barnes AC, Naomi B, George T, Louise McC, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12(4):233-46. DOI: https://doi.org/10.1016/S2213-8587(23)00385-6
O'Keefe JH, Franco WG, O'Keefe EL. Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy. Progress Cardiov Dis. 2024;89:102-12. DOI: https://doi.org/10.1016/j.pcad.2024.12.010
Rivera FB, Cruz LLA, Magalong JV, Ruyeras JMMJ, Aparece JP, Bantayan NRB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J Prevent Cardiol. 2024;18:100679. DOI: https://doi.org/10.1016/j.ajpc.2024.100679
Xie Y, Choi T, Al-Aly Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature Med. 2025;31(3):951-62. DOI: https://doi.org/10.1038/s41591-024-03412-w
Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients with Type 2 Diabetes. JAMA Network Open. 2024;7(7):e2421305. DOI: https://doi.org/10.1001/jamanetworkopen.2024.21305
Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molecular Psychiat. 2024;29(8):2587-98. DOI: https://doi.org/10.1038/s41380-024-02498-5
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Eng J Med. 2024;391(2):109-21. DOI: https://doi.org/10.1056/NEJMoa2403347
Lähteenvuo M, Tiihonen J, Solismaa A, Tanskanen, A, Mittendorfer-Rutz E, Taipale H. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiat. 2025;82(1):94-8. DOI: https://doi.org/10.1001/jamapsychiatry.2024.3599
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Eng J Med. 2023;389(24):2221-32. DOI: https://doi.org/10.1056/NEJMoa2307563
Pavli P, Triantafyllidou O, Kapantais E, Vlahos NF, Valsamakis G. Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature. Int J Molecul Sci. 2024;25(3):1909. DOI: https://doi.org/10.3390/ijms25031909
Sindhu U, Sharma A, Zawar I, Punia V. Newer glucose-lowering drugs reduce the risk of late-onset seizure and epilepsy: A meta-analysis. Epilep Open. 2024;9(6):2528-36. DOI: https://doi.org/10.1002/epi4.13091
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Eng J Med. 2024;391(13):1193-205. DOI: https://doi.org/10.1056/NEJMoa2404881
Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet. Gastroenterol Hepatol. 2024;8(6):511-22. DOI: https://doi.org/10.1016/S2468-1253(23)00068-7
Gorelik Y, Ghersin I, Lujan R, Shlon D, Loewenberg Weisband Y, Ben-Tov A, et al. GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the Epi-IIRN. J Crohn's Colitis JJAE. 2025;19(4):jjae160. DOI: https://doi.org/10.1093/ecco-jcc/jjae160
Guyton J, Jeon M, Brooks A. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus. Am J Health-System Pharmacy. 2019;76(21):1739-48. DOI: https://doi.org/10.1093/ajhp/zxz179
Pasqua MR, Tsoukas MA, Kobayati A, Aboznadah W, Jafar A, Haidar A. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nature Med. 2025;31(4):1239-45. DOI: https://doi.org/10.1038/s41591-024-03463-z
Qin W, Yang J, Deng C, Ruan Q, Duan K. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial. Diab Obes Metabol. 2024;26(3):911-23. DOI: https://doi.org/10.1111/dom.15386
Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Eng J Med. 2024;392(5):427-37. DOI: https://doi.org/10.1056/NEJMoa2410027
Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros B, Burguera E, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Med. 2024;30(7):2049-57.
Lassen MCH, Johansen ND, Modin D, Catarig AM, Vistisen BK, Amadid H, et al. Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study. Diab Obes Metabol. 2024;26(11):5239-50. DOI: https://doi.org/10.1111/dom.15872
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Pubpeer comments on Marso et al. Semaglutide and cardiovascular outcomes in patients with type 2 Diabetes. N Engl J Med. 2016;375(19):1834-44. DOI: https://doi.org/10.1056/NEJMoa1607141
Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. The effect of semaglutide on adverse events is inconclusive by fair and sound statistical approach: a comment on: “long term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial”. Nat Med. 2024;30(7):2049-57. DOI: https://doi.org/10.1038/s41591-024-02996-7
Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Systemat Rev. 2025;2(2):CD015849. DOI: https://doi.org/10.1002/14651858.CD015849.pub2
Lima GS, Figueira ALG, Carvalho EC, Kusumota L, Caldeira S. Resilience in Older People: A Concept Analysis. Healthcare (Basel, Switzerland). 2023;11(18):2491. DOI: https://doi.org/10.3390/healthcare11182491
Cal SF, de Sá LR, Glustak ME, Santiago MB. Resilience in chronic diseases: A systematic review, Cogent Psychol. 2015;2:1:1024928. DOI: https://doi.org/10.1080/23311908.2015.1024928
Downloads
Published
How to Cite
Issue
Section
